No Data
Due to caution against Trump's tariffs, it temporarily fell below the milestone of 38,000 yen.
The Nikkei average continued to decline. It finished trading at 38,134.97 yen, down 307.03 yen (volume estimated at 1.8 billion 20 million shares). Today, risk-averse selling continued against the backdrop of concerns over the global economy due to the upcoming Trump administration's tariff increases. Additionally, the yen appreciated, reaching the low 152 yen range against the dollar, negatively impacting export-related stocks, which caused the Nikkei average to widen its decline towards the end of the afternoon session, pushing down to 37,988.99 yen and dipping below the psychological threshold of 38,000 yen.
Active and newly listed stocks during the morning session.
*Dai-Doo Group HD <2590> 3240 +326 The cumulative operating profit for the third quarter has turned into an increase. *Janome <6445> 1187 +82 The upward trend in stock prices continues, and buybacks are becoming more active. *Keisei Electric Railway <9009> 4662 +243 Viewed as a material for the sale of shares in OLC shareholding. *Resonac <4004> 4170 +178 Interest as a related company to perovskite solar cells. *Oriental Land Co., Ltd. Unsponsored ADR <4661> 3585 +150 Responding to the sale of shares in Keisei Electric Railway.
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.